People with chronic heart, lung, kidney, or liver diseases often struggle to get quick answers in remote areas. Standard tests like spirometry or echocardiography require trained staff and expensive equipment. A new compact platform called VitoCheck aims to change this. It uses electrical signals to measure internal body changes without invasive procedures. The goal was to match the accuracy of standard hospital tests while working in community clinics. The study looked at how well this device predicted results for lung function, heart function, liver fat, and kidney filtration. It compared its readings against standard metrics like spirometry, ultrasound, and blood serum tests. The results showed the device made accurate predictions for all four areas. It also worked well when non-specialists operated it. This suggests the technology could help manage diseases proactively outside large hospitals. However, the team tested system stability and sensitivity using controlled phantom studies rather than real patients. This means the real-world performance in diverse clinical environments needs further confirmation. Despite this, the potential for scalable screening in out-of-clinic care is significant.
VitoCheck EIT platform predicts standard diagnostics for cardiopulmonary and metabolic diseasesA new device predicts heart and lung health without needing a specialist
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This cohort study in community settings evaluated the VitoCheck compact electrical impedance tomography platform for predicting standard diagnostic metrics. The population included clinical cohorts with chronic cardiopulmonary, metabolic, and renal diseases. The intervention was the VitoCheck platform, and the comparator was standard diagnostic metrics including spirometry, echocardiography, ultrasound, and blood serum tests.
The main results showed accurate EIT-based predictions of spirometry-derived forced expiratory volumes for lung function, echocardiography-derived ejection fraction for heart function, ultrasound-derived liver fat scores for liver function, and blood serum-derived kidney filtration for kidney function. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for these outcomes.
Safety and tolerability were not reported, including adverse events, serious adverse events, and discontinuations. Key limitations include that system stability, spatial specificity, and spectral sensitivity were demonstrated only through controlled phantom studies.
Practice relevance includes enabling scalable screening and proactive disease management for use in remote and out-of-clinic care. The evidence is preliminary and based on observational cohort data without reported quantitative performance metrics.